When the pure-hearted are lonely, they create a world of their own.
Hear your own voice.
Articles
The Start of Autumn — Wanwu Awaits the Harvest | Linear Quarterly
Spring sows, summer grows — the answer is on its way.
Qiming Star | Chinese Chassis-by-Wire Leader Nexteer Technology Successfully Lists on Hong Kong Exchanges and Clearing Limited
Qiming Venture Partners co-led NaSen Technology's Series A round in 2018 and continued to back the company in its Series B round.
To Video Models: If the Masses Don't Love You, Who Do You Think You Are?
🤡MemeBench Shocking Release
The Other Half of AGI
"She is everywhere."
Yunqi Partners | Physical intelligence startup "FeiJieKeSi" raises hundreds of millions of RMB in Series A1, with Yunqi Capital increasing its stake
Building a Solid Foundation for Domestic Physics-Based AI Technology
Dalton Venture Honored on Diyixinsheng's Q2 2026 China Most Active Investors Rankings, Winning "Top 30 Most Active Early-Stage Investment Institutions" and "Top 10 Most Active Healthcare Investment Institutions" | Dalton Honor
Recently, Diyixinsheng released its Q2 2026 China Most Active Investment Firms rankings. The list evaluated firms across multiple dimensions including investment activity, fundraising, exits, IPOs, service transactions, post-investment tech support, and market influence. **Dalton Venture was honored with two awards: "Top 30 Most Active Early-Stage Investment Firms" and "Top 10 Most Active Investment Firms in Healthcare."**
Registration Now Open | WRC On-Site Discussion: Where Is the Embodied Intelligence Wave Heading?
There is no single answer, only a direction of continuous evolution.
Evotrex raises over 200 million yuan in funding, first smart RV model to begin mass production in early 2027 | Unity Ventures portfolio news
Order volume continues to climb, significantly beating expectations, with multiple industry partnership deals materializing.
Qiming Star | Immune-Mediated Disease Leader Attovia Therapeutics Debuts on Nasdaq | Bilingual
Focused on developing next-generation biotherapeutics for immune-mediated diseases with significant unmet clinical needs.